EMEA-002585-PIP01-19
Key facts
| Active substance |
Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) for B-cell maturation antigen (BCMA) (JNJ-68284528)
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0353/2019
|
| PIP number |
EMEA-002585-PIP01-19
|
| Pharmaceutical form(s) |
Dispersion for infusion
|
| Condition(s) / indication(s) |
Treatment of Multiple Myeloma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Janssen-Cilag International N.V
Tel.: +353 857446696 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|